Western Daily Press (UK)
A cutting-edge cancer drug developed by experts at a West hospital has again been rejected for routine use on the NHS, sparking a major row between patients, the hospital, the drugs company and the Gover nment.
The Government's body that decides what drugs the NHS can afford, the
But NICE hit back, accusing the drug's manufacturers
One in five breast cancer sufferers have the HER-2 type, and existing treatments available on the NHS prolong their life expectancy by just over two years, on average, depending on how early the cancer is caught, and how healthy the patient is.
In the trials at RUH, Kadcyla was found to give an average of 30 months extra life, and to give much fewer side-effects, including hair loss and infections. Dr
At the moment, it is being prescribed by a special fund that GPs and consultants have to apply for. That only covers
"Kadcyla represents an important advance in the treatment of a particularly aggressive form of the disease; the decision not to fund it for routine NHS use is hugely disappointing," said Dr Beresford. "Kadcyla uses 'stable linker' technology to join a targeted antibody with a highly potent chemotherapy and has been shown to extend the lives of women while reducing many of the severe side effects commonly associated with chemotherapy - such as hair loss and infections.
"While women in
Dr Beresford had worked with the drug's creator
"NICE's rejection of Kadcyla demonstrates quite simply that their current system is broken, not fit for purpose and in need of a complete overhaul when it comes to advanced cancer," he said.
OPINION PAGE 15 Share your views
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.